Lonza’s bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct heterodimerization of light and heavy chains during bispecific production can be challenging, ...

Cardano continues to shine in research reports, praised for its academic rigor and governance innovations, keeping it in the spotlight among institutional ...

Light chain multiple myeloma (LCMM) is so-called because the myeloma cells are only able to produce the light chain protein and cannot produce the heavy chain protein.

Lonza’s bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct heterodimerization of light and heavy chains during bispecific production can be challenging, ...